Skip to content
value.today
Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

Total raised
$428 M
3 rounds on record
Latest round
$350 M
Mar 2024
First round on record
Oct 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Crinetics Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$350 MNo. 3$250 million to $1 billion

Crinetics Pharmaceuticals, Inc.: Raise no. 3, Mar 2024

Investors in this round

36 investors had bought by the notice of Mar 11, 2024: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Crinetics Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$350 M of $350 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$14,000,001
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dana Vivaldi Pizzuti · Executive Officer
  • James Vivaldi Hassard · Executive Officer
  • Jeff Vivaldi Knight · Executive Officer
  • Marc Scott Wilson · Executive Officer
  • RICHARD SCOTT STRUTHERS, PhD · Executive Officer, Director
  • Stephen Vivaldi Betz · Executive Officer
  • Camille Scott Bedrosian, M.D. · Director
  • Caren Scott Deardorf · Director
  • Matthew Scott Fust · Director
  • Rogerio Vivaldi Coelho, M.D. · Director
  • Stephanie Scott Okey · Director
  • WENDELL SCOTT WIERENGA, PhD · Director
  • WESTON SCOTT NICHOLS, PhD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LIFESCI CAPITAL, LLC (CRD 168404) · New York, New YorkSold in all US states
  • H.C. WAINWRIGHT & CO., LLC (CRD 375) · New York, New YorkSold in all US states
  • ROBERT W. BAIRD & CO. INCORPORATED (CRD 8158) · Milwaukee, WisconsinSold in all US states
  • PIPER SANDLER & CO. (CRD 665) · Minneapolis, MinnesotaSold in all US states
  • LEERINK PARTNERS LLC (CRD 39011) · New York, New YorkSold in all US states
  • CITIZENS JMP SECURITIES, LLC (CRD 22208) · San Francisco, CaliforniaSold in all US states

Signed by Marc Wilson, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 11, 2024. Read the notice at the SEC.

equitySEC
Feb 2018$60 MNo. 2$50 to $250 million

Crinetics Pharmaceuticals, Inc.: Raise no. 2, Feb 2018

Investors in this round

12 investors had bought by the notice of Feb 23, 2018: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Crinetics Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $65 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Marc Scott Wilson · Executive Officer
  • Richard Scott Struthers, Ph.D · Executive Officer, Director
  • Jack B. Nielsen · Director
  • Mason Scott Freeman, M.D. · Director
  • Matthew K. Fust · Director
  • Steve Scott Kaldor, Ph.D · Director
  • Wendell Scott Wierenga, Ph.D · Director
  • Weston K. Nichols, Ph.D · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Marc Wilson, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 23, 2018. Read the notice at the SEC.

equitySEC
Oct 2015$18 MNo. 1$10 to $50 million

Crinetics Pharmaceuticals, Inc.: Raise no. 1, Oct 2015

Investors in this round

8 investors had bought by the notice of Nov 16, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 15 investors are named for Crinetics Pharmaceuticals, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $40 M offered; $22 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$41,446 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard Scott Struthers · Executive Officer, Director
  • Stephen F. Betz · Executive Officer
  • YunFei F. Zhu · Executive Officer
  • Mahendra Scott Shah · Director
  • Mason Scott Freeman · Director
  • Steve Scott Kaldor · Director
  • Wendell Scott Wierenga · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Repayment of loan from executive officer to Issuer.”

Signed by Richard Scott Struthers, President and CEO. Source: SEC Form D, newest notice filed Nov 16, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Crinetics Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2024).

    SEC Form D · Mar 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2024

That is all the official record says: Crinetics Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

In its own words

How the company describes itself to search engines on its website, word for word.

“Crinetics is here for endocrine disease patients who are eager to find therapies that provide effective disease control and more simplicity in their lives.”

Source: The company's website · as of Nov 15, 2026

Products and services#

No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.

Investors#

15 named in official filings. Open an investor to see everything it has backed.

Investors in Crinetics Pharmaceuticals, Inc.
InvestorKindAmountRoundRoleSource
5AM Co-Investors IV, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
5AM Partners IV, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
5AM Ventures IV, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Perceptive Advisors LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Perceptive Life Sciences Master Fund LTDFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner, director (Form 3, 2018)SEC Form 3
Versant Affiliates Fund V, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Versant Ophthalmic Affiliates I, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Versant Venture Capital V (Canada), LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Versant Venture Capital V, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Vivo Capital Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Vivo Capital, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Vivo Capital Surplus Fund VIII, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Vivo Capital VIII, LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 36 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Crinetics Pharmaceuticals, Inc.
NameRoleNamed in
Dana Vivaldi PizzutiExecutive officerMar 2024
James Vivaldi HassardExecutive officerMar 2024
Jeff Vivaldi KnightExecutive officerMar 2024
Marc Scott WilsonExecutive officerMar 2024
RICHARD SCOTT STRUTHERS, PhDExecutive officerMar 2024
Stephen Vivaldi BetzExecutive officerMar 2024
Richard Scott Struthers, Ph.DExecutive officerFeb 2018
Richard Scott StruthersExecutive officerNov 2015
Stephen F. BetzExecutive officerNov 2015
YunFei F. ZhuExecutive officerNov 2015
Camille Scott Bedrosian, M.D.DirectorMar 2024
Caren Scott DeardorfDirectorMar 2024
Matthew Scott FustDirectorMar 2024
RICHARD SCOTT STRUTHERS, PhDDirectorMar 2024
Rogerio Vivaldi Coelho, M.D.DirectorMar 2024
Stephanie Scott OkeyDirectorMar 2024
WENDELL SCOTT WIERENGA, PhDDirectorMar 2024
WESTON SCOTT NICHOLS, PhDDirectorMar 2024
Jack B. NielsenDirectorFeb 2018
Mason Scott Freeman, M.D.DirectorFeb 2018
Matthew K. FustDirectorFeb 2018
Richard Scott Struthers, Ph.DDirectorFeb 2018
Steve Scott Kaldor, Ph.DDirectorFeb 2018
Wendell Scott Wierenga, Ph.DDirectorFeb 2018
Weston K. Nichols, Ph.DDirectorFeb 2018
Mahendra Scott ShahDirectorNov 2015
Mason Scott FreemanDirectorNov 2015
Richard Scott StruthersDirectorNov 2015
Steve Scott KaldorDirectorNov 2015
Wendell Scott WierengaDirectorNov 2015

About

Company in San Diego, United States.